Adaptimmune Therapeutics (ADAP)
(Delayed Data from NSDQ)
$1.08 USD
+0.02 (1.42%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.08 +0.01 (0.47%) 4:28 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ADAP 1.08 +0.02(1.42%)
Will ADAP be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ADAP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADAP
Adaptimmune (ADAP) Down on End of Collaboration With Roche
Adaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What You Should Know
ADAP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why
Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND
Adaptimmune Therapeutics PLC (ADAP) Loses -28.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Other News for ADAP
Adaptimmune: Huge Opportunity Amid Their Setback With Genentech
These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)
Leerink Partners Sticks to Its Hold Rating for Adaptimmune Therapeutics (ADAP)
12 Health Care Stocks Moving In Friday's After-Market Session
Analysts Have Conflicting Sentiments on These Healthcare Companies: Elevance Health (ELV) and Adaptimmune Therapeutics (ADAP)